Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic variants in 5p13.2 and 7q21.1 are associated with treatment for benign prostatic hyperplasia with the α-adrenergic receptor antagonist.

The aging male : the official journal of the International Society for the Study of the Aging Male - 1 Dec 2017

Qian Xiaoqiang, Xu Ding, Liu Hailong, Lin Xiaoling, Yu Yongjiang, Kang Jian, Sheng Xujun, Xu Jianfeng, Zheng Siqun, Xu Danfeng, Qi Jun

Abstract excerpt

BACKGROUND: The etiology of benign prostatic hyperplasia (BPH) has not been well established. The preferred medical treatment for many men with symptomatic benign prostatic hyperplasia is either an α-adrenergic receptor antagonist (α-blocker), or a 5α-reductase inhibitor. Single nucleotide polymorphism (SNP) is a powerful tool for successful implementation of individualized treatment. METHODS: Eighteen SNPs...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Case-Control Studies

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Disease Progression

Share to Polymorphism, Single Nucleotide

Share to Prostate

Share to Prostatic Hyperplasia

Source

Identifiers

PMID: 28787260
DOI: 10.1080/13685538.2017.1358261

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic variants in 5p13.2 and 7q21.1 are associated with treatment for benign prostatic hyperplasia with the α-adrenergic receptor antagonist.PMID 28787260Read ↗

SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.Semantic proximity Read ↗

Benign prostatic hyperplasia genetic variants in Asians.Semantic proximity Read ↗

Genetic variants in 2q31 and 5p15 are associated with aggressive benign prostatic hyperplasia in a Chinese population.Semantic proximity Read ↗

A genetic study to identify pathogenic mechanisms and drug targets for benign prostatic hyperplasia: a multi-omics Mendelian randomization study.Semantic proximity Read ↗

Polymorphisms in genes involved in sex hormone metabolism may increase risk of benign prostatic hyperplasia.Semantic proximity Read ↗

Polygenic risk score predicting susceptibility and outcome of benign prostatic hyperplasia in the Han Chinese.Semantic proximity Read ↗

Heritability and genome-wide association study of benign prostatic hyperplasia (BPH) in the eMERGE networkSemantic proximity Read ↗

Polygenic risk score predicting susceptibility and outcome of benign prostatic hyperplasia in the Han ChineseSemantic proximity Read ↗

Epidemiological investigation of sex hormones and their metabolism-related gene single nucleotide polymorphisms in patients with benign prostatic hyperplasia complicated with late-onset hypogonadism: a retrospective cohort studySemantic proximity Read ↗

Systematic review and meta-analysis of candidate gene association studies of benign prostate hyperplasia.Semantic proximity Read ↗

CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia.Semantic proximity Read ↗

Relationship of oestrogen receptor alpha gene polymorphisms with risk for benign prostatic hyperplasia and prostate cancer in Chinese men.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.